CF PharmTech climbs most in 4 weeks on product marketing application in Asia
28/05/2026 05:24
BUZZ-CF PharmTech climbs most in 4 weeks on product marketing application in Asia ** Shares of CF PharmTech Inc 2652.HK climb 7.1% to HK$21.06, on track for the biggest one-day pct gain since April 28
** Stock hits the highest point since May 20
** China-based innovator in inhalation drug delivery technology said it has submitted a marketing authorization application for CF017, a budesonide suspension for inhalation, to the relevant drug regulatory authority in a Southeast Asian market
** The submission of marketing authorization applications for CF017 in the Southeast Asian market marks a further step in the group's global strategy to extend its international commercialization footprint - Co
** YTD, stock down 42.3%, Hang Seng Biotech Index .HSBIO down 8.2%
(Reporting by Donny Kwok)
Recent news on CF PharmTech
See all newsBrief: CF Pharmtech Receives NMPA Implied Clinical Trial Approvals For ICF001 In IPF And PPF
Brief: CF Pharmtech To Place 21.7 MLN New H Shares At HK$13.82 Per Share
Brief: CF Pharmtech Says Nmpa Approves Ind Application For ICF004 As Class 1 New Drug
Brief: CF Pharmtech Inc To Nominate Zhang Jingjing As Candidate For Executive Director
CF PharmTech climbs most in 4 weeks on product marketing application in Asia